Denali Therapeutics Inc.
DNLI Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 23, 2026
$18.41
KIRA · Stoqly’s AI analyst, in plain words
- Denali Therapeutics Inc. had $0.0M of revenue in fiscal 2025.
- Denali Therapeutics Inc. lost $513M in fiscal 2025.
- Free cash flow was −$422M in fiscal 2025, — of revenue.
Market cap
$3.4B
P/E
—
Revenue
$0.0M
Net income
−$513M
Free cash flow
−$422M
Operating margin
—
Denali Therapeutics Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$513M
No. It lost money last year.
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Denali Therapeutics Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 26, 2026
- Legal name
- Denali Therapeutics Inc.
- CIK
- 0001714899
Denali Therapeutics Inc. · DNLI
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $48.7M | $108M | $331M | $0.0M | $0.0M |
| Revenue growth | −85.5% | 122.9% | 204.7% | −100.0% | — |
| Operating margin | −607.8% | −314.2% | −59.5% | — | — |
| Net income | −$291M | −$326M | −$145M | −$423M | −$513M |
| Net margin | −597.2% | −300.6% | −43.9% | — | — |
| Diluted EPS | −$2.39 | −$2.60 | −$1.06 | −$2.57 | −$2.97 |
| Cash | |||||
| Cash from operations | −$211M | −$245M | −$358M | −$348M | −$413M |
| Capital expenditure | $8.5M | $17.8M | $12.9M | $15.9M | $9.5M |
| Free cash flow | −$220M | −$263M | −$371M | −$364M | −$422M |
| FCF margin | −451.9% | −242.1% | −112.2% | — | — |
| Share count change | 7.8% | 3.3% | 9.4% | 19.7% | 5.0% |
| Debt and strength | |||||
| Cash and short-term investments | $865M | $1.3B | $1.0B | $832M | $868M |
| Shareholders' equity | $962M | $1.0B | $1.0B | $1.2B | $1.0B |
| Current ratio | 2.4x | 3.8x | 13.6x | 8.5x | 9.2x |
| Returns and quality | |||||
| Return on equity | −27.5% | −32.5% | −14.0% | −37.4% | −45.7% |
| Return on tangible equity | −30.2% | −31.3% | −14.1% | −34.4% | −50.6% |
| Piotroski F-score | 1 | 3 | 3 | 1 | 2 |
| Altman Z'' | 1.8 | 3.4 | 10.1 | 6.5 | 3.6 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$1.3M
4 insiders
Of sales under plans
25%
$0.3M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Denali Therapeutics Inc. · DNLI
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $18.41 a share, the company is worth $3.4B.
Source: SEC EDGAR XBRL filings (CIK 0001714899). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.